Physician profile
Ezra Cohen
NPI 1669400016
$19,031.53
in general payments reported to CMS, 2019-2025
69 companies · $3,541 in 2025
The $3,541 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,630 · 2020: $1,913 · 2021: $1,843 · 2022: $3,197 · 2023: $2,903 · 2024: $3,004 · 2025: $3,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,448.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,907.97 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $2,678.92 | 2021-2025 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $2,180.24 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $832.97 | 2019-2025 | Nuplazid, Daybue |
| Ucb, INC. | $723.02 | 2019-2025 | Nayzilam, Briviact |
| Pfizer INC. | $608.24 | 2022-2025 | |
| Biogen, INC. | $603.37 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Lundbeck LLC | $602.55 | 2019-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $582.94 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $576.37 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $558.33 | 2020-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $557.83 | 2019-2025 | Ultomiris, Soliris |
| Sunovion Pharmaceuticals INC. | $340.15 | 2019-2022 | |
| Allergan, INC. | $312.78 | 2019-2020 | |
| Celgene Corporation | $298.28 | 2021-2025 | Zeposia |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ezra Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.